Achillion Pharmaceuticals, Inc.

Other

Steven D Podos

Mingjun Huang

Thomas Mittag

Dharaben Patel

Janet B Serle

The dosages and methods described herein provide desirable pharmacokinetic (PK) and pharmacodynamics (PD) characteristics which inhibit alternative pathway complement activity, for example at least 85% or more inhibition of AP activity in vivo at dosages from about 120 mg to 200 mg BID that provides a plasma level Cat least about 65 ng/ml, which provides sufficient AP inhibition to reduce the risk of complement breakthrough. In addition, the dosage form described herein provides a significantly low C, providing additional safety margin and better dosing flexibility.

Targeted dosing for the treatment of complement mediated disorders

Provided herein are methods for treating a subject with PNH comprising administering to a subject a therapeutically effective amount of complement component C5 (C5) inhibitor, complement component C3 (C3) inhibitor, or complement factor B (CFB) inhibitor in combination with a therapeutically effective amount of small molecule complement factor D (CFD) inhibitor of Formula I or Formula II, or a pharmaceutically acceptable salt thereof.

Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria

This invention relates to a method of reducing intraocular pressure and treating glaucoma in mammals which comprises administering topically to the eye a pharmaceutically acceptable salt isomeric to yohimbine and stereochemically similar to corynanthine in an amount effective to reduce intraocular pressure.

Growing community of inventors

New Haven, CT, United States of America

Steven D Podos